Role of asymmetric dimethylarginine in cardiorenal syndrome

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2448-2455

  Ueda, Seiji ^a   Yamagishi, Sho ichi ^a   Yokoro, Miyuki ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asymmetric dimethylarginine; CKD; CVD; Dimethylarginine dimethylaminohydrolase; Endothelial dysfunction; Nitric oxide

Indexed keywords

6 N,N' DIMETHYLARGININE; ANGIOTENSIN RECEPTOR ANTAGONIST; DEOXYCORTICOSTERONE ACETATE; DIMETHYLARGININASE; EZETIMIBE; FENOFIBRATE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; ARGININE; CARDIOVASCULAR AGENT; N,N-DIMETHYLARGININE; NITRIC OXIDE SYNTHASE;

ALBUMINURIA; ARTICLE; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; GENE OVEREXPRESSION; HEMODIALYSIS PATIENT; HUMAN; HYDROLYSIS; HYPERTENSION; INFLAMMATION; KIDNEY INJURY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEINURIA; RISK FACTOR; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIO-RENAL SYNDROME; DRUG DELIVERY SYSTEM; METABOLISM; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ARGININE; CARDIO-RENAL SYNDROME; CARDIOVASCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NITRIC OXIDE SYNTHASE;

EID: 84903716434     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990480     Document Type: Article

References (134)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 2004; 351: 1296-305.
2. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 2006; 17: 2112-9.
3. Hallan SI, Matsushita K, Sang Y, et al. Age and Association of Kidney Measures With Mortality and End-stage Renal Disease. JAMA 2012; 30: 1-12.
4. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. BethesdaMD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
5. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-15.
6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85.
7. Liu PP. Cardio-Renal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol 2008; 24: 25B-9B.
8. Jois P, Mebazaa A. Cardio-Renal Syndrome Type 2: Epidemiology, Pathophysiology, and Treatment. Seminars in Nephrology, 2012; 32, 26-30.
9. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16.
10. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50.
11. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-30.
12. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997; 96: 379-82.
13. Cooke JP. Dose ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7.
14. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7.
15. Ueda S, Yamagishi S, Kaida Y, Okuda S. Asymmetric dimethylarginine (ADMA) may be a missing link between chronic kidney disease (CKD) and cardiovascular disease (CVD). Nephrology 2007; 12: 582-90.
16. Zoccali C. The endothelium as a target in renal diseases. J Nephrol 2007; 20: S39-44.
17. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-8.
18. Perticone F, Maio R, Perticone M, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010; 122: 379-84.
19. Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: role of ADMA in retarding renal disease progression. J Nephrol 2010; 23: 377-86.
20. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6.
21. Tarnow L, Hovind P, Teerlink T, et al. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-9.
22. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
23. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-7.
24. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006; 70: 781-7.
25. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary event and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-8.
26. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53-9.
27. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-61.
28. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-55.
29. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Pract 2001; 54: S65-72.
30. Ueda S, Matsuoka H, Miyazaki H, et al. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000; 35: 71-5.
31. Boger RH. The pharmacodynamics of L-arginine. J Nutr 2007; 137: 1650S-5S.
32. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-23.
33. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
34. Cross JM, Donald A, Vallance P, et al. Hemodialysis improves endothelial function in humans. Nephrol Dial Transplant 2001; 16: 1823-9.
35. Hibbs JB Jr, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 550-65.
36. Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269: H1522-7.
37. Segarra G, Medina P, Ballester RM, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999; 30: 2206-10.
38. Segarra G, Medina P, Vila JM, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001; 14: 1142-8.
39. Gardiner SM, Kemp PA, Bennett T, et al. Regional and cardiac haemodynamic effects of NG, NG, dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993; 110: 1457-64.
40. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996; 28: 439-46.
41. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 2001; 59: 1466-72.
42. Pollock JS, Forstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-4.
43. Jeserich M, Munzel T, Just H, Drexler H. Reduced plasma Larginine in hypercholesterolaemia. Lancet 1992; 339: 561.
44. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282: 879-87.
45. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthasedeficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-8.
46. Hasegawa K, Wakino S, Tatematsu S, et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 2007; 101: e2-10.
47. Luo Z, Teerlink T, Griendling K, et al. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension 2010; 56: 498-504.
48. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1: 65-73.
49. Schwedhelm E, Böger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011; 7: 275-85.
50. Schepers E, Glorieux G, Dhondt A, et al. Role of symmetric dimethylarginine in vascular damage by increasing ROS via storeoperated calcium influx in monocytes.
51. Schepers E, Barreto DV, Liabeuf S, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2374-83.
52. Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-34.
53. Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010; 208: 518-23.
54. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
55. Böger R, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105.
56. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nature Reviews Drug Discovery 2011; 10; 277-91.
57. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005; 10: S3-9.
58. Lee J, Sayegh J, Daniel J, et al. PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem 2005; 280: 32890-6.
59. Cook JR, Lee JH, Yang ZH, et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. Biochem Biophys Res Commun 2006; 342: 472-81.
60. Niu L, Lu F, Pei Y, et al. Regulation of flowering time by the protein arginine methyltransferase AtPRMT10. EMBO Rep 2007; 8: 1190-5.
61. Scebba F, De Bastiani M, Bernacchia G, et al. PRMT11: a new Arabidopsis MBD7 protein partner with arginine methyltransferase activity. Plant J 2007; 52: 210-22.
62. McBride A, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001; 106; 5-8.
63. Takahashi Y, Daitoku H, Hirota K, et al. Asymmetric Arginine Dimethylation Determines Life Span in C. elegans by Regulating Forkhead Transcription Factor DAF-16. Cell Metab 2011; 13: 505-16.
64. Yokoro M, Suzuki M, Murota K, et al. mmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes. Biosci Biotechnol Biochem 2012; 76: 1334-42.
65. Osanai T, Saitoh M, Sasaki S, et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42: 985-90.
66. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148: 671-7.
67. Kimoto M, Miyatake S, Sasagawa T, et al. Purification, cDNA cloning and expression of human NG, NG-dimethylarginine dimethylaminohydrolase. Eur J Biochem 1998; 258: 863-8.
68. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 1999; 343: 209-14.
69. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13: 199-203.
70. Hu X, Atzler D, Xu X, et al. cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 2011; 31: 1540-6.
71. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-40.
72. Ueda S, Kato S, Matsuoka H, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226-33.
73. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
74. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5.
75. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17 2176-83.
76. Kakimoto Y, Akazawa S. Isolation and identification of NG, NG-, and NG, N'G-dimethyl-arginine, N-mono-, di-, and trimethyllysine, and glucosylgalactosyl-, and galactosyl-d-hydroxylysine from human urine. J Biol Chem 1970; 245: 5751-8.
77. McDermott JR. Studies on the catabolism of NG-methylarginine, NG, N'G-dimethylarginine and NG, NG-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-84.
78. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-6.
79. Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int 2003; 84: S37-40.
80. Tain YL, Freshour G, Dikalova A, et al. Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 2007; 292: F1404-10.
81. Okubo K, Hayashi K, Wakino S, et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 2005; 28: 181-9.
82. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002; 99: 13527-32.
83. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
84. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004; 15: 77-80.
85. Markus C, Tasao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75.
86. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 2005; 45: 525-32.
87. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-6.
88. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339-45.
89. Kobayashi S, Oka M, Maesato K, et al. Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol 2008; 3: 1289-95.
90. Young JM, Terrin N, Wang X, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1115-20.
91. Lu TM, Chung MY, Lin CC, et al. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1566-72
92. Tripepi G, Mattace Raso F, Sijbrands E, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011; 6: 1714-21.
93. Kajimoto H, Kai H, Aoki H, et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 2012; 81: 762-8.
94. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Workihg Group. Am J Kidney Dis 2000; 36: 646-61.
95. Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension 1995; 25: 1202-11.
96. Arnal J-F, Michel J-B, Harrison DG. Nitric oxide in the pathogenesis of hypertension. Curr Opin Nephrol Hypertens 1995; 4: 182-8.
97. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
98. MacAllister RJ, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol 1994; 5: 1057-65.
99. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, Una, and vasoactive hormones in healthy humans. Am J Physiol 1996; 270: F845-51.
100. Ruilope LM, Lahera VK Rodicio JL, et al. Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens 1994; 12: 625-31.
101. Kielstein JT, Simmel S, Bode-Boger SM, et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004; 27: 143-7.
102. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-7.
103. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108: 3042-7.
104. Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008; 21: 38-44.
105. Schulze F, Maas R, Freese R, et al. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005; 35: 622-6.
106. Sydow K, Schmitz C, von Leitner EC, et al. Dimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertension. PLoS One 2012; 7: e48150.
107. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-7.
108. Kielstein JT, Bode-Böger SM, Frölich JC, et al. Asymmetric dimethylarginine, BP, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-5.
109. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-8.
110. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.
111. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 2106-11.
112. Arcos MI, Fujihara CK, Sesso A, et al. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol 2000; 279: F1060-6.
113. Sharma M, McCarthy ET, Savin VJ, Lianos EA. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int 2005; 68: 2735-44.
114. Yilmaz MI, Sonmez A, Saglam M, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008; 19: 388-95.
115. Sharma M, Zou Z, Miura H, et al. ADMA Injures Glomerular Filtration Barrier: Role of Nitric Oxide and Superoxide. Am J Physiol Renal Physiol. Am J Physiol Renal Physiol 2009; 296: F1386-95.
116. Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18: 1525-33.
117. Shibata R, Ueda S, Yamagishi S, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant 2009; 24: 1162-9.
118. Marliss EB, Chevalier S, Gougeon R, et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006; 49: 351-9.
119. Kaida Y, Ueda S, Yamagishi S, et al. Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome. Life Sci 2012; 91: 301-5.
120. Lajer M, Tarnow L, Jorsal A, et al. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008; 31: 747-52.
121. Hanai K, Babazono T, Nyumura I, et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009; 24: 1884-8.
122. Kang DH, Nakagawa T, Feng L, et al. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161: 239-48.
123. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 1434-47.
124. Nangaku M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
125. Fujimi-Hayashida A, Ueda S, Yamagishi S, et al. Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy. Am J Nephrol 2011; 33: 1-6.
126. Yilmaz MI, Saglam M, Sonmez A, et al. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007; 25: 327-35.
127. Achan V, Tran CT, Arrigoni F, et al. All-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90: 764-9.
128. Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255-62.
129. Hu T, Chouinard M, Cox AL, et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006; 281: 39831-8.
130. Onozato ML, Tojo A, Leiper J, et al. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Diabetes 2008; 57: 172-80.
131. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-8.
132. Yang TL, Chen MF, Luo BL, et al. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol 2005; 371: 401-7.
133. Stühlinger MC, Abbasi F, Chu JW, et al. lationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6.
134. Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product-Induced Protein Arginine Methyltranferase-1 Expression. Am J Pathol 2012 in press. doi: pii: S0002-9440(12)00729-8.